TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06197711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISMA
Description: PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions.
Study: NCT04609566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg given intravenously every 3 weeks
Study: NCT04530695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Periodontal treatment by scaling and root planing (SRP), deep cleaning
Study: NCT05385705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
Study: NCT06517927

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical and radiographic dental examination
Description: complete clinical oral examination + intra-oral and panoramic x-rays

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical and radiographic dental examination
Description: complete clinical oral examination + intra-oral and panoramic x-rays
Study: NCT06567327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin oral tablets
Study: NCT05198167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxygenated fatty acids
Description: Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Description: Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
Study: NCT06054880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigotindisulfonate sodium 0.8%
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigotindisulfonate sodium 0.8%
Description: Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection 0.9%
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection 0.9%
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection 0.9%
Description: Placebo
Study: NCT06157827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-024 for Injection
Description: Initial dose-MTD; Q3W; intravenous infusion
Study: NCT05096286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethos Therapy
Description: FDA-approved treatment planning system
Study: NCT04791813

Intervention type: OTHER
Intervention: Alginate impressions , Photographic data and panoramic radiographs .
Description: Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.

Intervention type: OTHER
Intervention: Alginate impressions , Photographic data and panoramic radiographs .
Description: Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
Study: NCT06000176

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: diagnostic test OCTA macula and ONH
Study: NCT05354804

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Troponin I (Siemens VTli) 0/1 hour algorithm
Description: Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm
Description: Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
Study: NCT06459141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute normovolemic hemodilution
Description: The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
Study: NCT05809739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE Hydro
Description: 3 sessions of injections (J0, J14 and J28)
Study: NCT05993871

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: distal leg 3mm punch skin biopsy
Study: NCT06500520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resisted Exercise group
Description: The resisted exercise training program targeted trunk, upper, and lower body segments with 10-12 repetitions at 30-65% intensity, lasting 50-60 minutes per session, 3 times weekly for 8 weeks. Participants determined their maximal repetition through trial training. Maximal power was assessed using concentric 1-maximal repetition (MT). Following a 2-3 minute rest and a 5-minute warm-up (walking), participants performed the 1-MT test to establish their heaviest lift with the correct technique, adjusting resistance levels accordingly. The circuit-style training spanned 9 stations with 2-3 sets per station, each circuit lasting 2-3 minutes with 90-second rests between sets. A 5-minute warm-up and cool-down (walking) preceded and followed each session. Exercises included bilateral elbow flexion, chest press, bilateral shoulder abduction, bilateral knee extension, back extension, sit-ups, knee flexion, hip abduction, and hip adduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercise group
Description: The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period. They were asked to do exercises such as trunk flexion, pelvic elevation, squatting, trunk lateral flexion, lumbar extensor stretching, lower abdominal stretching, hip adduct stretching, piriformis stretching, and trunk flexor stretching (cobra pose). The holding time was 5 seconds, the rest time was 1 second, and the exercises were applied in 10 repetitions.
Study: NCT04843813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein
Description: Participants will consume daily soft gels containing the lutein supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume daily soft gels containing the safflower oil.
Study: NCT06448026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV
Study: NCT06582602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
Study: NCT06641089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Sonelokimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Sonelokimab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Active comparator
Study: NCT05685238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8
Description: Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8
Description: Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
Study: NCT05882266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant Omega
Description: A commercial plant-based omega-3 beverage consumed once daily during breakfast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary therapy only
Description: Standard dietary therapy
Study: NCT06093191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalant Product
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral ciprofloxacin placebo
Description: Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ciprofloxacin placebo
Description: Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
Study: NCT05170568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD7 chimeric antigen receptor
Description: The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
Study: NCT06157827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab injection
Description: Initial dose; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
Study: NCT06244199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T2CR Intervention
Description: The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
Study: NCT05075577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Daily oral dose of enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 with Enzalutamide
Description: Daily oral dose of EPI-7386 in combination of enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 with Enzalutamide
Description: Daily oral dose of EPI-7386 in combination of enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 with Enzalutamide
Description: Daily oral dose of EPI-7386 in combination of enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 with Enzalutamide
Description: Daily oral dose of EPI-7386 in combination of enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 with Enzalutamide
Description: Daily oral dose of EPI-7386 in combination of enzalutamide
Study: NCT04980872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miransertib
Description: Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
Study: NCT04368130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIGNAL
Description: SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly.
Study: NCT05822999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WELT-IP
Description: WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
Study: NCT05916638

Intervention type: OTHER
Intervention: blood sample
Description: blood sample collection

Intervention type: OTHER
Intervention: blood sample
Description: blood sample collection
Study: NCT05533125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in 250ml NaCl 0.9% intravenously with usual premedication
Study: NCT06665568

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal ketamine hydrochloride
Description: Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
Study: NCT06669741

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One group will receive placebo therapy (identical shoulder brace and arm sleeve absent of semiconductor fabric)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Sleeve
Description: One group will receive active therapy (active semiconductor embedded shoulder brace and arm sleeve)
Study: NCT06670924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Running suture for vesico-urethral anastomosis in open radical prostatectomy
Description: The surgical technique of the RS followed the description of Van Velthovens, was applied with slight modifications. Two 3/0 absorbable monofilament (polydioxanone) sutures were used. The first needle is started from bladder neck at 3 o'clock, and terminated in the urethra at 9 o'clock. After completion of the posterior anastomosis, a transurethral catheter is placed. The second sutures' needle is passed from the bladder at 9 o'clock and ended in the urethra at 3 o'clock. The bladder neck and urethra are merged by gentle traction of the anterior and posterior sutures at 3 and 9 o'clock.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interrupted suture for vesico-urethral anastomosis in open radical prostatectomy
Description: The technique described by Walsh for interrupted anastomotic suturing was applied with minor modifications. Six 3/0 absorbable monofilament (polydioxanone) sutures were placed at 1, 3, 5, 7, 9 and 11 o'clock to accomplish the vesicourethral anastomosis.
Study: NCT06668428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Pharmacological and non-pharmacological methods are applied in the management of pain and anxiety after cesarean section (Tetik \& Tekinemre, 2017). In addition to medical treatment during the post-cesarean care process, complementary and supportive non-pharmacological approaches can be used to address the woman holistically and provide multi-faceted contributions to the health of the mother and baby (Ali, 2022; Bayraktar, 2023). One of the non-pharmacological approaches, virtual reality glasses, is a device that provides two or three-dimensional environments to stimulate our senses by creating illusions of images (Appel et al., 2021). SGG creates a therapeutic effect by diverting attention, provides relaxation, and can thus be used in the management of pain and anxiety (Ayed et al., 2019). It has been determined that virtual reality glasses are an effective method in the management of pain and anxiety in the field of nursing (Akıncı \& Aydın Özkan, 2024).
Study: NCT06673407

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Exposure for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from our previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during our quality improvement project, that are designed to enhance compassion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Enhanced Group Exposure Therapy for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety
Description: Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from our previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during our quality improvement project, that are designed to enhance compassion. These groups are facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.